Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer ...

Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The sto ...

The quest to mitigate disability progression in multiple sclerosis (MS) has long been hindered by our limited understanding ...

The State CET Cell, Maharashtra, has announced the registration schedule for the Additional MAH BCA/BBA/BMS/BBM CET 2025, following public requests for a re-exam. Registration runs from June 12 to ...

Objectives To develop a consensual definition for the term ‘early axial spondyloarthritis—axSpA’—and ‘early peripheral spondyloarthritis—pSpA’. Methods The ASAS (Assessment of SpondyloArthritis ...

The State CET Cell, Maharashtra has announced the MAH CET 2025 results for BCA, BBA, BMS, and BBM programmes today, June 4, 2025. Candidates can access their results using their registered ...

Beyond the upfront payment, the deal calls for BMS to pay $2 billion in non-contingent anniversary payments through 2028. BioNTech is also eligible to receive up to $7.6 billion in milestone payments.

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B for the German biotech.

BMS will pay an upfront cost of $1.5bn, as well as $2bn in non-contingent anniversary payments through 2028. In addition, BioNTech will be eligible to receive up to $7.6bn in development ...

The agreement, set against the backdrop of the ongoing 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, will mean BMS and BioNTech jointly share development and manufacturing costs on ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R ...